ImClone buoyed by new Erbitux data

ImClone has been buoyed by the news that Erbitux plus chemotherapy was better than chemotherapy alone in progression-free survival of colon cancer. Patients in the late-stage study given Erbitux and irinotecan demonstrated a 54 percent improvement in patient survival without new tumor growth. That was a secondary endpoint. The primary endpoint of overall mortality was not achieved. A second trial showed that Erbitux alone improved survival times and slowed tumor growth. Professor Derek Joner, co-chair of the study and assistant professor at the University of Ottawa, said that this was the first time that a single therapeutic proved effective in improving survival times.

- check out this release on the data
- for more, read the report from Crain's New York Business

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.